American College of Radiology (ACR)

The American College of Radiology represents diagnostic radiologists, radiation oncologists, interventional radiologists, nuclear medicine physicians and medical physicists. The society represents more than 41,000 diagnostic and interventional radiologists, radiation oncologists, nuclear medicine physicians and medical physicists. ACR helps members, through advocacy, quality and safety, and innovation, and serves as the voice of radiology, demonstrating value and setting standards to advance the field and practice.

RSS icon
Arl Van Moore, MD, American College of Radiology (ACR) delegate to the American Medical Association (AMA) House of Delegates, former ACR president, chairman of the ACR Board and former CEO of Strategic Radiology, discusses two radiology related policy decisions at the AMA 2022 meeting. These included a AMA policy on the iodine contrast shortage and AUC CDS. #AMA #AMA22 #AMAmtg #AMA175 #ACR

VIDEO: Radiology takeaways from the 2022 AMA meeting

Arl Van Moore, MD, American College of Radiology (ACR) delegate to the American Medical Association House of Delegates, former ACR president, chairman of the ACR Board and former CEO of Strategic Radiology, discusses radiology-related policy decisions at the AMA 2022 meeting.

Iodine contrast being loaded into a contrast injector in preparation for a cardiac CT scan at Duly Health and Care in Lisle, Illinois. The contrast shortage is causing some healthcare organizations to postpone exams and procedures and ration contrast supplies. Photo by Dave Fornell

ACR working with FDA and HHS to help address imaging contrast shortage

The American College of Radiology (ACR) announced this week its government relations staff has been engaging federal agencies in an effort to improve product availability and hasten resolution of the ongoing iodine contrast shortage.

A comparison between a traditional iodine contrast angiogram (left), and a gadolinium contrast angiogram (right). MRI gadolinium contrast is starting to be used in some interventional radiology procedures and is being considered in interventional cardiology due to the iodine contrast shortage.

Gadolinium can be used as substitute for iodine contrast in some interventional imaging procedures

Gadolinium might be an alternative, stop-gap solution for interventional procedures during the current iodine contrast shortage.

The imaging iodine contrast shortage is delaying procedures and causing rationing at hospitals. impact is it having on hospitals and the tough decisions that are being made to triage patients to determine if they will get a contrast CT scan or an interventional or surgical procedure requiring contrast. Photo by Dave Fornell

VIDEO: Imaging contrast shortage is delaying procedures and causing rationing

Alan H. Matsumoto, MD, chair of the department of radiology at the University of Virginia and vice chair of the American College of Radiology Board of Chancellors, explains the contrast shortage situation and the tough decisions providers are being forced to make.

Thumbnail

How radiology should prepare for AUC clinical decision support reporting requirements

An overview for the coming January 2023 mandate to use clinical decision support for all advanced imaging orders.

Thumbnail

Radiology leaders call on imaging community to create blueprint for digital image exchange by 2024

With technology now enabling seamless data transfer, it has become “unacceptable” to force patients and their families to hand-deliver images, experts charged in JACR.

ACR, SBI call for mammo screening beginning at 40

Less than two months after the U.S. Preventive Services Task Force set off a national controversy with its revised recommendations for mammography screening, the American College of Radiology (ACR) and the Society of Breast Imaging (SBI) have issued recommendations calling for breast cancer screening to begin at age 40 and even earlier for high-risk patients.

Displaying 17 - 23 of 23

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.